FDA OKs Drug Application by Gensia Sicor
- Share via
Dow Jones
Gensia Sicor Inc.’s pharmaceuticals unit received approval from the Food and Drug Administration for its abbreviated new drug application for daunorubicin hydrochloride for injection.
Irvine-based Gensia Sicor said daunorubicin hydrochloride is a drug for remission induction in acute myelogenous leukemia in adults and acute lymphocytic leukemia in children and adults.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
